For tirzepatide users, pauses, switches, access issues, or stopping can change the weight and appetite timeline. Tracking keeps the signal visible.
In SURMOUNT-4, participants who continued tirzepatide maintained or extended weight loss, while those switched to placebo regained weight. That supports a practical tracking point: stopping or pausing can change trajectory, and the change may show up through appetite and weekly trend before it feels obvious.
| Track | Why |
|---|---|
| Medication timeline | Zepbound/Mounjaro dose, last dose, pause, restart, switch, access issue. |
| Appetite and cravings | Hunger 0-10, fullness duration, late-night eating, alcohol interest. |
| Weekly trend | Weight average, waist, clothing-fit note, strength/steps. |
| Side effects | GI symptoms, fatigue, sleep, mood, injection-site issues. |